Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico‐pathologic correlation. (1st March 2021)

• Record Type: Journal Article
• Authors: Moya‐Martínez, Cristina; Torre‐Castro, Juan; Fariña‐Sabarís, Mª Carmen; Santiago Sánchez‐Mateos, Diana; Eraña‐Tomás, Itziar; Jo‐Velasco, Margarita; Requena, Luis
• Is Part Of: Journal of cutaneous pathology. Volume 48:Number 6(2021)
• Page Start: 789
• Page End: 794
• Publication Date: 2021-03-01
• Subjects: cutaneous drug eruption -- endothelial atypia -- PI3K inhibitors; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.13981
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract: Targeted anticancer therapy is being used with greater frequency and dermatologic toxicities are among the most frequent adverse events of these drugs. However, histopathological features of these adverse events are not yet well characterized. We present two cases of clinically different cutaneous toxicities on two patients with hematologic neoplasia. They were treated with different drugs and in both cases medications shared inhibition of PI3K as mechanism of action. The skin biopsy specimen showed endothelial cell atypia with large nuclei and mitotic figures. To the best of our knowledge, no other cases with these striking histopathologic findings have been reported with PI3K inhibitors or other anticancer targeted therapy.